Article
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
JCI insight - 9 Feb 2017
Lee Lynn H, Gasilina Anjelika, Roychoudhury Jayeeta, Clark Jason, McCormack Francis X, Pressey Joseph, Grimley Michael S, Lorsbach Robert, Ali Siraj, Bailey Mark, Stephens Philip, Ross Jeffrey S, Miller Vincent A, Nassar Nicolas N, Kumar Ashish R
Abstract excerpt
Many patients with histiocytic disorders such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester disease (ECD) have treatment-refractory disease or suffer recurrences. Recent findings of gene mutations in histiocytoses have generated options for targeted therapies. We sought to determine the utility of prospective sequencing of select genes to further characterize mutations and identify targeted therapies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.